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Abstract RNA interference (RNAi) is the process by which
double-stranded RNA directs sequence-speci¢c degradation of
mRNA. In mammalian cells, RNAi can be triggered by 21-nu-
cleotide duplexes of short interfering RNA (siRNA). We exam-
ined e¡ects of siRNA on hepatitis B virus (HBV) replication.
Human hepatoma cells were transfected with HBV DNA and
siRNA against HBV-pregenome RNA. Transfection experi-
ments demonstrated that the siRNA reduced the amount of
HBV-pregenome RNA and resulted in reduction of the levels
of replicative intermediates and viral protein. Our results indi-
cate that siRNA-mediated gene silencing inhibits HBV replica-
tion through suppression of viral RNA, which may be useful as a
potential therapeutic modality.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
RNA interference (RNAi) is a mechanism of gene regula-
tion in plants, invertebrates and, more recently, in mammalian
cells in which target mRNAs are degraded in a sequence-spe-
ci¢c manner [1^3]. RNAi is initiated by the double-stranded
RNA (dsRNA)-speci¢c endonuclease Dicer, which promotes
processive cleavage of long dsRNA into 21^23-mer short in-
terfering RNA (siRNA) [4^8]. siRNAs are incorporated into a
protein complex that recognizes and cleaves target mRNA [5^
8]. RNAi has been shown to protect against invading genetic
elements such as transposons, transgenes and viruses, which
potentially share a long dsRNA trigger [9^12].
In mammalian cells, exposure to dsRNAs greater than 30 bp
in length induces an antiviral interferon response that gener-
ally represses mRNA translation through the activation of
dsRNA-dependent protein kinase [13]. However, introduction
of shorter siRNA into mammalian cells leads to mRNA deg-
radation with exquisite sequence speci¢city without activating
the interferon system [3]. RNAi-mediated gene silencing o¡ers
a potentially powerful tool to inhibit viral replication. There-
fore, we examined whether siRNA duplexes speci¢c for hep-
atitis B virus (HBV) were capable of a¡ecting the degradation
of viral RNAs.
2. Materials and methods
2.1. Plasmids and synthesis of siRNA
Full-length HBV DNA was cloned via SacI site into the pGEM-
11Zf(+) vector (Promega, Madison, WI, USA) as described previously
[14], registered in GenBank (accession number AB050018). According
to Harborth’s report for selection of siRNA duplexes for the target
mRNA sequence [15], we searched for sequences of the type AA
(N21) [N, any nucleotide (nt)] from the open reading frame of the
3.5-kb HBV-pregenome RNA, in order to obtain a 21-nt sense and
21-nt antisense strand with 2-nt 3P overhangs. A selected sequence was
also submitted to a BLAST search against the human genome se-
quence to ensure that the human genome was not targeted. siRNA
with the following sense and antisense sequences was used: siHBV, 5P-
CAUUGUUCACCUCACCAUATT-3P (sense), 5P-UAUGGUGAG-
GUGAACAAUGTT-3P (antisense), corresponding to HBV sequence
in the core region from nt 2137 to nt 2157 (Fig. 1). siRNA against
green £uorescent protein was used as control: siGFP, 5P-GGCUAC-
GUCCAGGAGCGCACC-3P (sense), 5P-UGCGCUCCUGGACGU-
AGCCTT-3P (antisense). All siRNAs were purchased from Nihon
Bioservice (Saitama, Japan).
2.2. Cells and transfections
The HuH7 and HepG2 cells, human hepatoma cell lines, were
maintained in RPMI, supplemented with 10% fetal bovine serum.
Prior to transfection, plasmid including HBV genome was cleaved
with SapI (New England Biolabs, Beverly, MA, USA) to release the
heterologous primer sequences and to create linear HBV monomers
with SapI sticky ends, as described previously by Gunther et al. [16].
The digested DNA was puri¢ed by a QIAquick PCR puri¢cation kit
(Qiagen, Hilden, Germany). Transfection of cells using linear mono-
meric HBV genome with SapI ends can initiate a full replication cycle,
including production of viral RNAs, translation of viral proteins and
release of virions [14,16]. The HuH7 and HepG2 cells were plated at a
density of 2.5U105 and 4.0U105 cells per 35-mm-diameter dish, re-
spectively. One day later, both cells were transfected with 0.5 Wg of
HBV DNA and 0.05 Wg of pGL3-control vector expressing luciferase
(Promega) together with 100 pmol of each siRNA, using oligofect-
amine (Gibco-Invitrogen, Rockville, MD, USA) according to the pro-
tocol provided by the manufacturer. The medium was replaced with a
fresh medium 6 h after transfection, and the cells were harvested
2 days after transfection. Experiments were performed in triplicate.
Transfection e⁄ciency was standardized by measurement of the lucif-
erase activity in the cell lysate using a luciferase assay system (Prom-
ega).
2.3. Quantitative assay of viral marker
The levels of hepatitis B surface antigen (HBsAg) and hepatitis B e
antigen (HBeAg) in culture media from transfected cells were quanti-
tatively measured using chemiluminescent immunoassay and radioim-
munoassay (Dainabot, Tokyo, Japan), respectively.
2.4. Northern blotting
Total RNA was isolated from the transfected HuH7 cells using the
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guanidium isothiocyanate method. The isolated RNA was fractionat-
ed on 1.5% formaldehyde agarose gel, transferred onto a nylon mem-
brane (Hybond Nþ, Amersham, Little Chalfont, UK), and hybridized
with a 32P-labeled full-length HBV fragment. The probe was gener-
ated with a random-primed labeling kit (Amersham). Autoradiogra-
phy was performed and analyzed with a BAS2000 image analyzer
(Fuji Photo Film, Tokyo).
2.5. Southern blotting
Puri¢cation of HBV DNA from intracellular core particles was
performed using the method described by Gunther et al. [16]. Brie£y,
the cells were washed once with ice-cold phosphate-bu¡ered saline
and lysed in 300 Wl of lysis bu¡er [50 mM Tris^HCl (pH 7.4), 1 mM
EDTA, 1% Nonidet P-40] per 35-mm-diameter dish. The cell lysates
were transferred to 1.5-ml tubes, vortexed, and allowed to stand on
ice for 15 min. Nuclei were pelleted by centrifugation for 1 min at
14 000 rpm. The supernatant was adjusted to 10 mM MgCl2 and
treated with 100 Wg ml31 of DNase I for 30 min at 37‡C. The reaction
was stopped by addition of EDTA to a ¢nal concentration of 25 mM.
Proteins were digested with 0.5 mg ml31 of proteinase K and 1%
sodium dodecyl sulfate for 2 h at 37‡C. Nucleic acids were puri¢ed
by phenol^chloroform (1:1) extraction and ethanol precipitation with
glycogen. DNA isolated from the cytoplasmic core particles was sep-
arated on a 1.5% agarose gel, blotted onto a nylon membrane (Hy-
bond Nþ), and hybridized with a 32P-labeled full-length HBV frag-
ment.
3. Results
3.1. Quantitative analysis of viral markers in culture media
siRNA duplexes were co-transfected with a full-length HBV
DNA into the HuH7 and HepG2 cells. HBsAg and HBeAg
secreted into culture media were quantitatively assayed (Fig.
2). The amount of HBsAg in media of cells transfected with
siHBV did not di¡er from that of cells transfected with siGFP
(control siRNA). In contrast, medium HBeAg levels in cells
transfected with siHBV decreased to 4.6-fold and 4.9-fold in
comparison with cells transfected with siGFP in HuH7 and
HepG2 cells, respectively.
3.2. Northern and Southern blot analysis
Northern blot analysis was performed 2 days after trans-
fection (Fig. 3). The level of 2.4/2.1-kb mRNA of HBV was
not suppressed by siHBV, whereas the level of 3.5-kb mRNA
was reduced in cells transfected with siHBV relative to cells
transfected with siGFP.
Using Southern blot analysis (Fig. 4), the level of open
circular and single-stranded HBV-DNA, which is considered
as an intracellular replicative intermediate, was clearly sup-
pressed by siHBV. On the other hand, the level of double-
stranded HBV-DNA, which is mostly derived from the trans-
fected DNA, was slightly diminished.
Fig. 1. A schematic diagram depicting the location of the siRNA in association with viral open reading frames and viral mRNAs within the
HBV genome.
Fig. 2. Quantitative measurements of HBsAg (A) and HBeAg (B) in
culture media from HuH7 cells and HepG2 cells co-transfected with
HBV DNA and siRNA. Transfection experiments were performed
in triplicate as described in Section 2. The levels of medium HBsAg
and HBeAg are expressed as meanTS.D. The S/N ratio denotes the
signal-to-noise ratio.
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4. Discussion
Gene silencing mediated by siRNA is a sequence-speci¢c
and highly conserved mechanism in eukaryotes [9^11]. In
plants, it serves as an antiviral defense mechanism [12]. Mam-
malian cells also possess this machinery but its speci¢c func-
tion is unclear. More recently, several investigators demon-
strated that siRNAs inhibit HIV-1 production by targeting
various regions for its genome [17,18]. In this study, we
showed that siRNAs directed against HBV genome could ef-
fectively block viral replication.
The HBV genome is a partially double-stranded 3.2-kb
DNA molecule and is the template transcribed to generate
the four viral RNAs [19]. The 3.5-, 2.4/2.1-, and 0.7-kb tran-
scripts encode the core protein/HBeAg and polymerase-re-
verse transcriptase, HBsAg, and X protein, respectively. All
viral transcripts utilize a common polyadenylation signal lo-
cated within the core protein-coding region. The 3.5-kb
mRNA not only serves for translation of the core protein/
HBeAg and polymerase-reverse transcriptase but also repre-
sents the template for reverse transcription. In the present
study, the e¡ect of RNAi on HBV replication was examined
using a siRNA speci¢c for the 3.5-kb pregenome RNA, which
did not bind to other viral transcripts. We demonstrated that
the siRNAs reduced the level of 3.5-kb pregenome RNA and
resulted in reduction of the levels of secreted HBeAg and
replicative intermediates converted from the 3.5-kb prege-
nome RNA. These ¢ndings indicate that mammalian RNAi
machinery can be programmed with siRNA corresponding to
HBV genome to induce an e¡ective antiviral response. Unsur-
Fig. 3. Northern blot analysis of HBV in cells co-transfected with HBV DNA and siRNA. A: The HuH-7 cells were harvested 2 days after
transfection. The amount of 3.5- and 2.4/2.1-kb HBV mRNA was determined by Northern blotting. B: The hybridization signals for the viral
transcript were quantitatively evaluated by NIH image analysis software. Data are expressed as meanTS.D. relative to the value of cells trans-
fected with siGFP in three independent transfection experiments.
Fig. 4. Southern blot analysis of HBV in cells co-transfected with HBV DNA and siRNA. A: The HuH-7 cells were harvested 2 days after
transfection. The level of open circular (oc), double-stranded (ds) and single-stranded (ss) HBV DNA was determined by Southern blotting.
The lane denoted PC was loaded with linear full-length HBV. B: The HBV DNA signals obtained from three independent transfection experi-
ments were quantitatively evaluated by NIH image analysis software. Data are expressed as meanTS.D. relative to the value of cells trans-
fected with siGFP.
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prisingly, the levels of 2.4/2.1-kb mRNA and secreted HBsAg
was not reduced in cells transfected with siHBV, since the 2.4/
2.1-kb mRNA did not include the homologous sequence to
siHBV.
Although chronic HBV infection is a major health problem
worldwide, there is no completely e¡ective antiviral treatment.
siRNA technology may provide a possible therapeutic strat-
egy against chronic HBV infection. Further studies are neces-
sary to determine the antiviral mechanism of siRNA on HBV
replication.
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